<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638689</url>
  </required_header>
  <id_info>
    <org_study_id>2010-019363-11</org_study_id>
    <secondary_id>2010-019363-11</secondary_id>
    <nct_id>NCT01638689</nct_id>
  </id_info>
  <brief_title>A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram</brief_title>
  <official_title>A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      Healthy males were examined with positron emission tomography (PET) and the radioligand&#xD;
      11C-AZ10419369, before and after administration of a single dose escitalopram. A change in&#xD;
      the binding potential of 11C-AZ10419369 between the baseline and the post-dose condition was&#xD;
      hypothesized to reflect a change in serotonin concentration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in binding potential of 11C-AZ10419369 between baseline and post-dose condition</measure>
    <time_frame>One day (PET measurement before and after escitalopram administration on the same day)</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>20 mg p.o.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Male gender&#xD;
&#xD;
          3. Age 20 to 30 years&#xD;
&#xD;
          4. Healthy according to physical examination, ECG, MRI and blood chemistry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past or present psychiatric disease&#xD;
&#xD;
          2. Past or present brain disorder or injury, including loss of consciousness for more&#xD;
             than five minutes&#xD;
&#xD;
          3. Past or present drug or alcohol abuse&#xD;
&#xD;
          4. Past or present use of antidepressant or antipsychotic medications&#xD;
&#xD;
          5. Regular use of medications (including herbals), that could interfere with the&#xD;
             pharmacodynamics or pharmacokinetics of escitalopram&#xD;
&#xD;
          6. Significant abnormality on ECG&#xD;
&#xD;
          7. Structural abnormality in the brain confirmed by MR examination&#xD;
&#xD;
          8. Claustrophobia&#xD;
&#xD;
          9. Any metal devises or implants in the body&#xD;
&#xD;
         10. Intolerance to escitalopram or any of the components of the formula&#xD;
&#xD;
         11. Predisposition to motion sickness&#xD;
&#xD;
         12. Inability to understand and comply with the study requirements&#xD;
&#xD;
         13. Any medical condition that, in the opinion of the investigator, make the subject&#xD;
             unsuitable for the study or put the subject at additional risk&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Nord, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PET center, Department of Clinical neuroscience, Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>S-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Magdalena Nord</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Mechanism of Action of escitalopram</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

